ARTICLE | Clinical News
Amphinex: Phase II discontinued
June 29, 2015 7:00 AM UTC
PCI Biotech discontinued the open-label, European Phase II ENHANCE trial of 0.25 mg/kg IV Amphinex followed by laser therapy. The company cited increased competition by emerging immunotherapies for th...